Natera Q2 Revenue Jumps 38 Percent, Company Raises Full-Year Outlook by $100 Million
The cell-free DNA testing company processed approximately 283,000 Signatera tests en route to revenue of $752.8 million.
Natera said on Aug. 6 that its second quarter revenue rose 38 percent year over year, driven by strength in its Signatera test.
The Austin, Texas-based cell-free DNA and genetic testing company reported Q2 revenue of $752.8 million, up from $546.6 million in Q2 2025, beating the consensus Wall Street estimate. Product revenues grew 37 percent to $747.9 million from $544.4 million a year ago.
“We had an exceptional quarter helping patients, with over one million tests processed for the second consecutive quarter and record growth in oncology volumes,” CEO Steve Chapman said in a statement.
In Aug. 7 trading on the Nasdaq, shares of Natera were up 20 percent at $320.19.
Natera processed approximately 1,040,000 tests in the quarter, up 22 percent from approximately 853,000 in Q2 2025. Oncology test volume grew 57 percent year over year to approximately 296,000 tests from approximately 188,000 a year ago. Signatera test volume grew 56 percent year over year to 283,000 clinical tests.
The company’s net loss for the quarter was $67.0 million, or $.47 per share, compared to a loss of $100.9 million, or $.74 per share, in Q2 2025, beating the consensus estimate for a loss of $.52 per share.
Natera’s R&D expenses rose 56 percent to $228.1 million from $146.4 million in Q2 2025. SG&A expenses rose 5 percent to $327.2 million from $310.5 million a year ago.
As of June 30, Natera had $1.09 billion in cash, cash equivalents, and restricted cash.
Natera raised its full-year 2026 revenue guidance by $100 million at the midpoint to $2.85 billion to $2.91 billion, from a prior range of $2.74 billion to $2.82 billion.